Almac Group Announces Support of Agios' PYRUKYND®

Article

Almac Group confirms it has supported Agios Pharmaceuticals, Inc., in the clinical trial and commercial launch of PYRUKYND® (mitapivat).

The treatment is the first FDA approved, disease-modifying therapy for adults with hemolytic anemia caused by PK (pyruvate kinase) deficiency, a rare, debilitating, and lifelong form of anemia.

Read more about the work between Almac Group and Agios here.

Recent Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.